Beam Therapeutics Inc.
| NASDAQ: BEAM |
| Healthcare / Biotechnology / USA |
| 40.40 | -2.69 | -6.24% | Vol 1.13M | 1Y Perf -60.41% |
| Jun 28th, 2022 16:00 DELAYED |
| BID | 39.94 | ASK | 42.30 | ||
| Open | 43.06 | Previous Close | 43.09 | ||
| Pre-Market | - | After-Market | 40.50 | ||
| - - | 0.10 0.25% |
| Target Price | 95.38 | Analyst Rating | Strong Buy 1.44 | |
| Potential % | 136.09 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★ 45.66 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 11.40 | Earnings Rating | — | |
| Market Cap | 2.84B | Earnings Date | 9th Aug 2022 | |
| Alpha | 0.03 | Standard Deviation | 0.29 | |
| Beta | 1.60 |
Today's Price Range 39.9043.10 | 52W Range 27.77138.52 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 13.25% | ||
| 1 Month | 19.46% | ||
| 3 Months | -27.04% | ||
| 6 Months | -45.11% | ||
| 1 Year | -60.41% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -88.34 | |||
ROE last 12 Months | -38.08 | |||
ROA (5Y Avg) | -12.25 | |||
ROA last 12 Months | -22.20 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -30.98 | |||
Return on invested Capital Q | -7.09 | |||
Return on invested Capital Y | -55.84 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.30 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -11.90 | ||||
| 3.60 | ||||
| 50.24 | ||||
| 14.80 | ||||
| 20.20 | ||||
| 2.88 | ||||
| 3.60 | ||||
| 11.80 | ||||
| 1.91B | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.60 | ||||
| 5.70 | ||||
| 0.14 | ||||
| 0.18 | ||||
| -1 066.00 | ||||
| Leverage Ratio | 1.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -445.20 | ||||
| -429.70 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 60.27M | ||||
| 0.86 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2022 | -1.10 | -1.01 | 8.18 |
| Q04 2021 | -1.02 | -0.85 | 16.67 |
| Q03 2021 | -0.78 | -0.42 | 46.15 |
| Q02 2021 | -0.58 | -0.95 | -63.79 |
| Q01 2021 | -0.72 | -3.35 | -365.28 |
| Q04 2020 | -0.70 | -0.72 | -2.86 |
| Q03 2020 | -0.57 | -0.69 | -21.05 |
| Q02 2020 | -0.56 | -0.69 | -23.21 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 9th Aug 2022 |
| Estimated EPS Next Report | -1.08 |
| Estimates Count | 5 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.13M |
| Shares Outstanding | 70.27K |
| Shares Float | 61.02M |
| Trades Count | 22.22K |
| Dollar Volume | 46.15M |
| Avg. Volume | 1.43M |
| Avg. Weekly Volume | 1.57M |
| Avg. Monthly Volume | 1.43M |
| Avg. Quarterly Volume | 1.29M |
Beam Therapeutics Inc. (NASDAQ: BEAM) stock closed at 43.09 per share at the end of the most recent trading day (a 1.36% change compared to the prior day closing price) with a volume of 1.05M shares and market capitalization of 2.84B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 166 people. Beam Therapeutics Inc. CEO is John Evans.
The one-year performance of Beam Therapeutics Inc. stock is -60.41%, while year-to-date (YTD) performance is -45.93%. BEAM stock has a five-year performance of %. Its 52-week range is between 27.77 and 138.5219, which gives BEAM stock a 52-week price range ratio of 11.40%
Beam Therapeutics Inc. currently has a PE ratio of -11.90, a price-to-book (PB) ratio of 3.60, a price-to-sale (PS) ratio of 50.24, a price to cashflow ratio of 14.80, a PEG ratio of 2.32, a ROA of -22.20%, a ROC of -30.98% and a ROE of -38.08%. The company’s profit margin is -%, its EBITDA margin is -429.70%, and its revenue ttm is $60.27 Million , which makes it $0.86 revenue per share.
Of the last four earnings reports from Beam Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.08 for the next earnings report. Beam Therapeutics Inc.’s next earnings report date is 09th Aug 2022.
The consensus rating of Wall Street analysts for Beam Therapeutics Inc. is Strong Buy (1.44), with a target price of $95.38, which is +136.09% compared to the current price. The earnings rating for Beam Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Beam Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Beam Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.09, ATR14 : 3.89, CCI20 : 144.06, Chaikin Money Flow : 0.30, MACD : 0.92, Money Flow Index : 69.78, ROC : 7.24, RSI : 61.88, STOCH (14,3) : 93.89, STOCH RSI : 1.00, UO : 71.01, Williams %R : -6.11), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Beam Therapeutics Inc. in the last 12-months were:
Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises of Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.
CEO: John Evans
Telephone: +1 857 327-8775
Address: 26 Landsdowne Street, Cambridge 02139, MA, US
Number of employees: 166
TipRanks News for BEAM
Wed, 11 May 2022 01:57 GMT Beam Therapeutics (BEAM) Gets a Hold Rating from RBC Capital
- TipRanks. All rights reserved.Mon, 10 Jan 2022 16:30 GMT Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM) and Karyopharm Therapeutics (KPTI)
- TipRanks. All rights reserved.
